Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CytoGam® as Adjuvant Therapy to Prevent or Attenuate Human Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant Recipients

NCT07009548 is registered in ClinicalTrials.gov with Fernanda P Silveira, MD, MS as lead sponsor.

NCT NCT07009548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07009548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CytoGam® as Adjuvant Therapy to Prevent or Attenuate Human Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant Recipients
Lead sponsor
Fernanda P Silveira, MD, MS
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
June 26, 2025
Completion date
December 31, 2027
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv) infection